Status:
ACTIVE_NOT_RECRUITING
Effectiveness of PGx Testing
Lead Sponsor:
Kaiser Permanente
Collaborating Sponsors:
OneOme, LLC
Conditions:
Polypharmacy
Eligibility:
All Genders
18-79 years
Phase:
NA
Brief Summary
The purpose of this study is to determine the clinical and economic effectiveness of a pharmacogenomic (PGx) approach to prescribing medications in patients with high-risk polypharmacy in an integrate...
Detailed Description
The purpose of this study is to determine the clinical and economic effectiveness of a pharmacogenomic (PGx) approach to prescribing medications in patients with high-risk polypharmacy in an integrate...
Eligibility Criteria
Inclusion
- 18-79 years of age
- Days supply of 5+ medications with 2+ advisable for PGx on the RightMed test
- English or Spanish speaker
- Current KPCO member
- Dispensing 1 med (for advisable for PGx) in the 90 days prior with no dispensing in the previous six months -or- daily dose change (up or down) in the 90 days
- Prescriber from Smoky Hill, Westminster, Hidden Lake, Skyline, East Denver, or Lakewood clinics
- Available email address -
Exclusion
- Pregnant (HCG+ test in the previous 9 months)
- A live birth in the previous 24 months
- SNF or hospice stay in the previous 1 month
- Hospitalization in previous 14 days
- Diagnosis of dementia, delerium, alzheimer's, or parkinson's in the previous 6 months
- On the KPCO No Contact List -
Key Trial Info
Start Date :
November 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2027
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT04120480
Start Date
November 15 2019
End Date
December 31 2027
Last Update
August 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Central Support Services
Aurora, Colorado, United States, 80011